Hypertension and nephrology - 2015;19(06)

Content

Journal Special issues Previous issue Next number Archives

Hypertension and nephrology

DECEMBER 10, 2015

[Role of nephroclinicopathology in the nephrological diagnosis]

NAGY Judit, KEMÉNY Éva, IVÁNYI Béla

[In cases where a definitive diagnosis of a renal disease cannot be established on the basis of the clinical and laboratory data as well as imaging techniques the histological examination of the renal biopsy can be useful for establishing a pathological diagnosis, assessing the prognosis and can give etiopathogenetic information to guide the further management. The description and the degree of the active and chronic changes may influence the rationale treatment and the likelihood of the... tovább »

PDF| Summary Cite COPYRIGHT FEES

HUN

2015;19(06)

Hypertension and nephrology

DECEMBER 10, 2015

[Diagnostic of genetic factors affecting blood pressure and the genetic risk factorsof hypertension]

LACZIKÓ Dorottya, RÉPÁSI Eszter, RZEPIEL Andrea, KEREKES Éva, SHENKER-HORVÁTH Kinga, KOLLER Ákos, ELBERT Gábor, NAGY Zsolt B.

[Hypertension is a risk factor of cardiovascular and renal diseases. Although high blood pressure usually does not show symptoms, it can lead to serious health problems such as stroke or cardio and renal insufficiency. Globally 40% of adults over the age of 24 suffer from hypertension, and the risk increases with age. The incidence is more than 70% over 65 years of age. Environmental and genetic effects are jointly responsible for the onset of hypertension, thereby determining predisposing... tovább »

PDF| Summary Cite COPYRIGHT FEES

HUN

2015;19(06)

Hypertension and nephrology

DECEMBER 10, 2015

[Application of central sympatholytic agents and vasodilators between 2007-2014 based on OEP’s database]

BARNA István, GYURCSÁNYI András

[Due to the a large number of antihypertensive drugs on the Hungarian market, in the light of the constantly updated recommendations for therapy, seemed to be worth to consider the traffic data provided by the National Health Insurance. We analysed the turnover of the centrally-acting and direct vasodilator antihypertensive, using the data of The National Health Insurance Fund (NHIF) between 2007 and 2014. Every year the December data were comparesed, the turnover of the month did not... tovább »

PDF| Summary Cite COPYRIGHT FEES

HUN

2015;19(06)

Hypertension and nephrology

DECEMBER 10, 2015